NEW YORK / May 28, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Jefferies Global Healthcare Conference Format: Presentation Date and Time:... Read More

NEW YORK / May 27, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed’s executive leadership team... Read More

NEW YORK / May 19, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 53,350 common shares of the Company (the... Read More

NEW YORK / May 13, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at the 2025 RBC Capital Markets Global Healthcare Conference: 2025 RBC Capital Markets Global Healthcare Conference... Read More

Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026 Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama Company to host a conference call today at 8:00 a.m. EDT... Read More

NEW YORK / Apr 24, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business... Read More

NEW YORK / Apr 21, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 121,500 common shares of the Company (the... Read More

Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between MM120 Orally Disintegrating Tablet (ODT) 100 µg and placebo Emerge builds on positive Phase 2b study results in generalized anxiety disorder (GAD), which showed MM120’s potential antidepressant effects Topline data from the... Read More

NEW YORK / Mar 24, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company (the... Read More

NEW YORK / Mar 17, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his... Read More

First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025 Raised approximately $250 million in gross proceeds through two equity financings in 2024;... Read More

NEW YORK / Mar 04, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference: Leerink’s Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings... Read More

NEW YORK / Feb 20, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended December 31, 2024, and discuss... Read More

NEW YORK / Feb 04, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference: Oppenheimer 35 th Annual Healthcare Life Sciences Conference... Read More

Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo Panorama builds on positive Phase 2b study results presented at the... Read More

NEW YORK / Dec 19, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transformational year for MindMed. We’ve... Read More

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo Study builds on positive Phase 2b study results presented at the American... Read More

NEW YORK / Dec 11, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024... Read More

Innovation Passport Designation Aims to Accelerate Time to Market and Facilitate Patient Access to Innovative Medicines NEW YORK / Dec 05, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide... Read More

NEW YORK / Dec 03, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and... Read More

NEW YORK / Dec 02, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 171,000 common shares of the Company (the "Options"),... Read More

NEW YORK / Nov 18, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance... Read More

NEW YORK / Nov 13, 2024 / Business Wire / Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Jefferies London Healthcare Conference Format: 1x1 Meetings Dates: November... Read More

On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026 On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025 Cash and cash equivalents of $295.3... Read More

NEW YORK / Oct 24, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the third quarter ended... Read More

NEW YORK / Sep 09, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 70,000 common shares of the Company (the "Options"),... Read More

NEW YORK / Sep 04, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: H.C. Wainwright 26 th Annual Global Investment Conference Format: Panel Panel... Read More

Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024 Expanding pipeline with MM120 ODT clinical program in Major Depressive Disorder (MDD) with plans to initiate a registrational study in first half of 2025 New patent issued by the... Read More

NEW YORK / Aug 09, 2024 / Business Wire / Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share, and, to certain investors,... Read More

NEW YORK / Aug 09, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public... Read More

NEW YORK / Aug 06, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Canaccord Genuity’s 44 th Annual Growth Conference: Canaccord Genuity’s 44th Annual Growth Conference Format: Fireside... Read More

NEW YORK / Aug 06, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Tuesday, August 13, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the second quarter ended June... Read More

NEW YORK / Jul 29, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corporate Affairs... Read More

New patent covers MM120 ODT formulation and extends patent term to 2041 Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT NEW YORK / Jul 17, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, today announced the... Read More

NEW YORK / Jun 28, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000 ® Index and the broad-market Russell 3000 ® Index,... Read More

NEW YORK / Jun 21, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the... Read More

Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD Initiation of Phase 3 program remains on schedule to begin in second half of 2024 NEW YORK / Jun 20, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the... Read More

NEW YORK / May 28, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences: BIO International Convention 2024 Panel Name: Challenging Biotech’s One-Track Mind When it... Read More

NEW YORK / May 09, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: 2024 RBCCM Global Healthcare Conference Format: Fireside Chat Date and Time:... Read More

GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life- People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments for... Read More

Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment of GAD in adults Cash and cash equivalents of $252.3 million as of March 31, 2024 Company to host a conference call... Read More

-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate- -MindMed also presents two new epidemiology studies quantifying the burden of GAD in the US- -APA Annual Meeting, the largest psychiatric gathering in the world, is... Read More

NEW YORK / May 02, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the first quarter ended March 31,... Read More

NEW YORK / Apr 25, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing... Read More

NEW YORK / Apr 02, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:... Read More

All Common shares will remain listed on Nasdaq NEW YORK / Apr 01, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on... Read More

NEW YORK / Mar 11, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in... Read More

NEW YORK / Mar 07, 2024 / Business Wire / Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. In addition, the... Read More

A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate MindMed plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA) in the first half of 2024 and initiate its Phase 3 clinical program in the second... Read More

Data update includes 12-week topline Phase 2b results for MM120 in Generalized Anxiety Disorder (GAD) Results from Phase 1 pharmacokinetics bridging trial for MM120 oral dissolving tablet (ODT) formulation to be discussed NEW YORK / Mar 01, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product... Read More

Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD) Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024 Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD) Conference call to... Read More

NEW YORK / Feb 22, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, February 28, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the year... Read More

NEW YORK / Feb 07, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference: 34th Annual Oppenheimer... Read More

Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for multiple data readouts and catalysts throughout 2024 including initiation of Phase 3 clinical program Proof-of-Concept study evaluating repeated sub-perceptual dose (20 μg) of lysergide in adults with Attention-Deficit/Hyperactivity Disorder (ADHD) did not meet primary... Read More

Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo at Week 4 (p=0.0004, Cohen’s d effect size = 0.88) Clinical response rate of 78% in 100 µg and 200 µg dose groups and... Read More

Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated by the end of Q1 2024 MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 Cash and cash equivalents of $117.7 million at September 30, 2023 Company to host conference call today at 4:30 PM ET NEW YORK / Nov 02, 2023 / Business Wire / Mind Medicine (MindMed) Inc.... Read More

NEW YORK / Oct 26, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter... Read More

53 participants enrolled across two sites NEW YORK / Oct 24, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has completed enrollment of Study MMED007, the Company’s Phase 2a study evaluating repeated low-dose administration of... Read More

Preclinical data in ASD model demonstrate the differences between MM-402 (R-MDMA), S-MDMA and Racemic MDMA with enhanced pro-social effects and reduced hyperactivity NEW YORK / Oct 03, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today the... Read More

NEW YORK / Sep 14, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday,... Read More

198 participants dosed across 20 clinical sites On track for topline results in Q4 2023 NEW YORK / Sep 12, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has completed enrollment and dosing in Study MMED008, the Company’s Phase 2b... Read More

NEW YORK / Aug 28, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: H.C. Wainwright Annual Global Investment Conference Format: Fireside... Read More

Enhances financial flexibility through multiple clinical catalysts on MM-120 and MM-402 product candidates The Company’s ending 2Q2023 cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations into 2026, if certain milestones are achieved that unlock additional capital $15.0 million drawn at loan closing NEW YORK / Aug 14, 2023 / Business Wire / Mind Medicine (MindMed) Inc.... Read More

Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 Entered into exclusive license agreement with Catalent for MM-120 Zydis® orally disintegrating tablet (ODT) formulation for advancement into pivotal... Read More

NEW YORK / Aug 03, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access... Read More

NEW YORK / Jul 31, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, August 3, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended... Read More

NEW YORK / Jun 22, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference: H.C. Wainwright 4th Annual... Read More

NEW YORK / Jun 21, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees – CEO Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone – to the Board of Directors (the “Board”) at the Annual Meeting of... Read More

NEW YORK / Jun 20, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, will provide an overview of clinical progress and corporate updates during an Investor Day today focused primarily on the MM-120 (lysergide D-tartrate) program in generalized anxiety... Read More

FCM Believes MindMed Is Threatening to Violate NASDAQ Requirements Imperiling MindMed’s Listing and Future Liquidity for Shareholders Failure to Satisfy Quorum Requirement at Annual Meeting Demonstrates Lack of Shareholder Support FCM Believes MindMed’s Announced Plan to Hold Shareholder Meeting Regardless of Level of Shareholder Participation Represents Appalling Corporate Governance Vote on FCM’s BLUE Proxy to Restore... Read More

Meeting Will Resume on Wednesday, June 21, 2023 Believes FCM Has Made Deliberate Efforts to Prevent Quorum from Being Achieved MindMed Encourages Shareholders to Vote FOR All Six of the Company’s Director Candidates on the WHITE Universal Proxy Card NEW YORK / Jun 15, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that the Company’s Annual... Read More

Proxy Cards Must be Received by 10:00 AM EDT on Tuesday, June 13 th for Votes to Count Encourages Shareholders to Vote on the WHITE Universal Proxy Card FOR ALL SIX of the Company’s Director Nominees NEW YORK / Jun 09, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today urged shareholders to vote FOR the election of all six of MindMed’s highly qualified director... Read More

Both Leading Proxy Advisory Firms – ISS and Glass Lewis – Now Recommend Support For All MindMed’s Nominees and Concluded FCM Has Not Made a Compelling Case for Change Glass Lewis Notes Company’s Director Nominees Possess the “Appropriate Experience and Qualifications” to Continue Leading MindMed MindMed Encourages Shareholders to Follow ISS and Glass Lewis’s Recommendation and Vote on the WHITE Universal Proxy Card FOR ALL... Read More

FCM Confident in Ability to Start MM-120 Phase III in 2023 and Obtain FDA Approval In 2026 Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period For Selling Shares Until June 15, 2026 Time is Running Out to Save MindMed Vote on FCM’s BLUE Proxy to Restore Shareholder Value at MindMed SHERIDAN, Wyo., June 07, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), representing approximately 3.5% of the outstanding... Read More

NEW YORK / Jun 07, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that its management team will a host an Analyst Day in New York City on Tuesday, June 20 th , 2023 that will focus on the MM-120 program in generalized anxiety disorder... Read More

ISS Believes Company’s Director Nominees Represent an “Unusually Strong” Group of Current and Former Executives From Relevant Fields and Are Best Suited to Continue Overseeing MindMed’s Strategy Concludes There is “No Reasonable Basis” to Question MindMed’s Drug Development Strategy or Third-Party Support From Greenleaf Health Confirms FCM Has Not Made a Compelling Case for Change; ISS Does Not Recommend Any of Dissident’s... Read More

FCM Predicts That the Psychedelic Revolution Will Begin with the FDA’s Likely Groundbreaking Approval of the Drug MDMA, Which is Expected to Occur in the Second Half of 2024 Reiterates that MindMed Must Be Prepared to Leverage this Opportunity FCM’s Plan Will Cut Excessive Spending and Focus Resources on its Flagship Drug LSD (MM-120) FCM Plan Will Have MindMed Start Phase III for MM-120 by End of 2023 and Positioned to... Read More

NEW YORK / Jun 01, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: BIO International Convention Format: Investor Presentation Date and... Read More

FCM Director Candidates, including Dr. Freeman, and Mr. Jake Freeman, Commit to Not Selling Any of Their MindMed Shares Until June 15, 2025 FCM and its Nominees Stand Behind Their Plan to Drive Value for Shareholders If FCM’s Plan is Enacted, FCM Believes MindMed’s Shares Will be Substantially More Valuable in Two Years Vote on FCM’s BLUE Proxy to Restore MindMed SHERIDAN, Wyo., May 30, 2023 (GLOBE NEWSWIRE) -- FCM MM... Read More

MindMed has Slashed Allocation of Spending on Core Drugs While Executive Compensation has Soared to $51M MindMed Phase IIb Clinical Trial Delayed Greenleaf Health Study, Quoting FDA, Supports FCM’s Plan to Immediately Start an LSD Phase III Trial FCM Publishes Presentation Outlining Overwhelming Case for Change at MindMed and Detailing Plan to Bring LSD Drugs to Millions in Need Urges Shareholders to Vote on FCM’s BLUE Proxy... Read More

Details Why MindMed’s Ideally Qualified Nominees Are the Right Choice to Oversee the Company’s Strategic Execution as it Approaches First Clinical Data Readouts Later this Year Urges Shareholders to Protect Their Investments and Vote on the WHITE Universal Proxy Card for ALL SIX of the Board’s Nominees NEW YORK / May 25, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or... Read More

Independent Third-Party Firm, Led by Former Senior FDA Officials, Calls Phase 2b Trial “Well-designed” and “Essential” Report Further Demonstrates that FCM’s Proposal to Skip Phase 2 for MM-120 – a Cornerstone of its Plan – is Unrealistic and Would Put MindMed Shareholders’ Investments at Risk Visit www.ProtectMindMed.com for More Information NEW YORK / May 25, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ:... Read More

Preclinical data in ASD model demonstrate prosocial effects of MM-402 NEW YORK / May 24, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today the upcoming presentation of preclinical data of MM-402, the Company’s proprietary form of the... Read More

Over 50% of patients dosed across 20 active clinical sites On Track for Topline Results in late 2023 NEW YORK / May 17, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that the company’s Phase 2b study evaluating MM-120 (lysergide... Read More

FCM Believes MindMed Focused on Pursuing Misguided Clinical Path for MM-120 MindMed Executives, Advisors – Barrow, Karlin, and Liechti – Do Not Have Experience in Bringing Drugs to Market and Are Making Fundamental Errors in Approach MindMed Cash Expected to Run Out in 2024 and Dilution Set to Soar FCM Nominees Have Brought Drugs to Market and Completed Numerous Phase III Trials FCM’s Highly Qualified Nominees Would Start... Read More

MindMed Board has Presided over Botched Regulatory Strategies, Outsized Expenses, Soaring Executive Compensation, and Value Destructive Financings FCM’s Four Highly Qualified Director Nominees to Bring Desperately Needed Accountability, Expertise, and Fresh Shareholder Focused Perspective to the Board Urges MindMed Shareholders to vote FOR All Four of FCM’s Nominees on the BLUE Proxy Card SHERIDAN, Wyo., May 05, 2023 (GLOBE... Read More

Key MM-120 readouts in GAD (Phase 2b) and ADHD (Phase 2a) expected by end of 2023 MM-402 pre-clinical data in ASD model to be presented at ASCP 2023 Annual Meeting Strengthened leadership team with appointment of Mark R. Sullivan as Chief Legal Officer Cash and cash equivalents of $129.4 million at March 31, 2023 Company to host conference call today at 4:30 PM ET NEW YORK / May 04, 2023 / Business Wire / Mind Medicine... Read More

Files Definitive Proxy Materials in Connection with June 15, 2023 Annual Meeting Board’s Nominees Possess Essential Pharmaceutical Industry, Capital Allocation and Corporate Governance Experience Needed to Drive Company’s Success at Pivotal Moment – With Two Key Clinical Readouts Expected Later This Year Believes FCM’s Nominees Lack Relevant Experience and are Unqualified to Serve as MindMed Directors – Let Alone Take... Read More

NEW YORK / May 01, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, May 4, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended... Read More

NEW YORK / Apr 26, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: H.C. Wainwright BioConnect Conference Format: 1x1 Investor Meetings... Read More

Meaningful Change is Needed at MindMed After Years of Poor Performance FCM’s Candidates Have Decades of Relevant Industry Experience and are Laser Focused on Bringing MM-120 to Market FCM to Provide Detailed Operational Plan to Address MindMed’s Operational Challenges SHERIDAN, Wyo., April 21, 2023 (GLOBE NEWSWIRE) -- Today, FCM MM Holdings, LLC ("FCM") announces that it has filed a preliminary proxy statement (the “Proxy... Read More

Presents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and New Independent Candidate David W. Gryska Highlights Significant Positive Momentum to Advance R&D Pipeline and Enhance Shareholder Value Discloses FCM MM HOLDINGS’ Intent to Take Control of the Board Through Nomination of Four Director Candidates FCM’s Nominees Lack Relevant Industry Expertise and Experience to Drive Long-Term... Read More

Primary endpoint achieved statistically significant improvement in MDD symptoms Confirmation of activity of lysergide in brain health disorders with direct relevance to MindMed’s MM-120 program in Generalized Anxiety Disorder (GAD) Data presented on April 14, 2023 in Basel, Switzerland NEW YORK / Apr 14, 2023 / Business Wire / Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical... Read More

NEW YORK / Apr 13, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary. “We are very excited to welcome Mark to our management team. Mark... Read More

NEW YORK / Mar 09, 2023 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the full-year ended December 31, 2022. “Our significant progress in 2022 has set the stage for what we expect to be a transformational 2023,"... Read More

Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 Company to initiate first clinical trial of MM-402 in 2023 Cash runway to fund current operating plan into first half of 2025 Company to host a virtual analyst and investor day in the first half of 2023 NEW YORK , Jan. 9, 2023 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or... Read More

NEW YORK , Dec. 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference. Canaccord Genuity New Paradigms and... Read More